Alseres Pharmaceuticals, Inc. (ALSE)
USD 0.01
(100.0%)
USD 0.01
(100.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2013 | 7.81 Million USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | -100.0% |
| 2010 | 30.5 Thousand USD | -99.91% |
| 2009 | 34.25 Million USD | 1.93% |
| 2008 | 33.6 Million USD | 44.01% |
| 2007 | 23.33 Million USD | 0.0% |
| 2006 | - USD | -100.0% |
| 2005 | 274.32 Thousand USD | 0.0% |
| 2004 | - USD | -100.0% |
| 2003 | 3.81 Million USD | -1.52% |
| 2002 | 3.86 Million USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | -100.0% |
| 1999 | 4.6 Million USD | 0.0% |
| 1998 | - USD | 0.0% |
| 1997 | - USD | 0.0% |
| 1996 | - USD | -100.0% |
| 1995 | 700 Thousand USD | 250.0% |
| 1994 | 200 Thousand USD | -33.33% |
| 1993 | 300 Thousand USD | -25.0% |
| 1992 | 400 Thousand USD | 100.0% |
| 1991 | 200 Thousand USD | 0.0% |
| 1990 | 200 Thousand USD | 0.0% |
| 1989 | 200 Thousand USD | 100.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2014 Q2 | 8.29 Million USD | 2.07% |
| 2014 Q1 | 8.12 Million USD | 3.95% |
| 2013 FY | 7.81 Million USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 Q4 | 7.81 Million USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2011 Q1 | 12.52 Thousand USD | -58.95% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 FY | - USD | -100.0% |
| 2011 Q2 | - USD | -100.0% |
| 2010 Q1 | 34.42 Million USD | 0.49% |
| 2010 Q3 | 28.92 Million USD | -16.38% |
| 2010 Q4 | 30.5 Thousand USD | -99.89% |
| 2010 FY | 30.5 Thousand USD | -99.91% |
| 2010 Q2 | 34.59 Million USD | 0.5% |
| 2009 Q3 | 34.08 Million USD | 0.48% |
| 2009 Q2 | 33.92 Million USD | 0.48% |
| 2009 Q4 | 34.25 Million USD | 0.49% |
| 2009 Q1 | 33.76 Million USD | 0.47% |
| 2009 FY | 34.25 Million USD | 1.93% |
| 2008 FY | 33.6 Million USD | 44.01% |
| 2008 Q4 | 33.6 Million USD | 0.94% |
| 2008 Q3 | 33.29 Million USD | 0.14% |
| 2008 Q2 | 33.24 Million USD | 18.37% |
| 2008 Q1 | 28.08 Million USD | 20.35% |
| 2007 Q2 | 14.54 Million USD | 61.58% |
| 2007 FY | 23.33 Million USD | 0.0% |
| 2007 Q4 | 23.33 Million USD | 0.52% |
| 2007 Q3 | 23.21 Million USD | 59.63% |
| 2007 Q1 | 9 Million USD | 0.0% |
| 2006 FY | - USD | -100.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 Q2 | - USD | -100.0% |
| 2006 Q1 | 261.33 Thousand USD | -4.74% |
| 2006 Q3 | - USD | 0.0% |
| 2005 FY | 274.32 Thousand USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q4 | 274.32 Thousand USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 FY | - USD | -100.0% |
| 2004 Q1 | 3.9 Million USD | 2.4% |
| 2004 Q2 | - USD | -100.0% |
| 2004 Q3 | - USD | 0.0% |
| 2003 FY | 3.81 Million USD | -1.52% |
| 2003 Q2 | 3.87 Million USD | 7.36% |
| 2003 Q3 | 3.93 Million USD | 1.52% |
| 2003 Q4 | 3.81 Million USD | -3.21% |
| 2003 Q1 | 3.61 Million USD | -6.64% |
| 2002 Q1 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2002 FY | 3.86 Million USD | 0.0% |
| 2002 Q4 | 3.86 Million USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 Q1 | - USD | -100.0% |
| 2000 FY | - USD | -100.0% |
| 2000 Q4 | - USD | 0.0% |
| 1999 FY | 4.6 Million USD | 0.0% |
| 1999 Q4 | 4.6 Million USD | 6.98% |
| 1999 Q3 | 4.3 Million USD | 0.0% |
| 1999 Q2 | - USD | 0.0% |
| 1999 Q1 | - USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| 1998 Q1 | - USD | 0.0% |
| 1998 Q3 | - USD | 0.0% |
| 1998 Q4 | - USD | 0.0% |
| 1998 Q2 | - USD | 0.0% |
| 1997 Q4 | - USD | 0.0% |
| 1997 FY | - USD | 0.0% |
| 1997 Q3 | - USD | 0.0% |
| 1997 Q2 | - USD | 0.0% |
| 1997 Q1 | - USD | 0.0% |
| 1996 Q4 | - USD | 0.0% |
| 1996 Q3 | - USD | 0.0% |
| 1996 Q2 | - USD | 0.0% |
| 1996 FY | - USD | -100.0% |
| 1996 Q1 | - USD | -100.0% |
| 1995 Q4 | 700 Thousand USD | 600.0% |
| 1995 FY | 700 Thousand USD | 250.0% |
| 1995 Q1 | 100 Thousand USD | -50.0% |
| 1995 Q2 | 100 Thousand USD | 0.0% |
| 1995 Q3 | 100 Thousand USD | 0.0% |
| 1994 FY | 200 Thousand USD | -33.33% |
| 1994 Q4 | 200 Thousand USD | 0.0% |
| 1994 Q3 | 200 Thousand USD | 0.0% |
| 1994 Q2 | 200 Thousand USD | 0.0% |
| 1994 Q1 | 200 Thousand USD | -33.33% |
| 1993 Q2 | 300 Thousand USD | -25.0% |
| 1993 FY | 300 Thousand USD | -25.0% |
| 1993 Q1 | 400 Thousand USD | 0.0% |
| 1993 Q3 | 300 Thousand USD | 0.0% |
| 1993 Q4 | 300 Thousand USD | 0.0% |
| 1992 Q1 | 100 Thousand USD | -50.0% |
| 1992 Q3 | 400 Thousand USD | 0.0% |
| 1992 Q4 | 400 Thousand USD | 0.0% |
| 1992 FY | 400 Thousand USD | 100.0% |
| 1992 Q2 | 400 Thousand USD | 300.0% |
| 1991 Q1 | 200 Thousand USD | 0.0% |
| 1991 Q4 | 200 Thousand USD | 0.0% |
| 1991 FY | 200 Thousand USD | 0.0% |
| 1991 Q3 | 200 Thousand USD | 0.0% |
| 1990 Q4 | 200 Thousand USD | 0.0% |
| 1990 FY | 200 Thousand USD | 0.0% |
| 1989 FY | 200 Thousand USD | 100.0% |
| 1989 Q4 | 200 Thousand USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | - USD | -Infinity% |
| Evofem Biosciences, Inc. | 8000.00 USD | -97649.5% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 1.75 Million USD | -345.46% |
| Qrons Inc. | 80 Thousand USD | -9674.95% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 20.31 Million USD | 61.501% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Skye Bioscience, Inc. | 171.23 Thousand USD | -4466.933% |
| Eiger BioPharmaceuticals, Inc. | - USD | -Infinity% |
| Nanobac Pharmaceuticals, Incorporated | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 20.9 Million USD | 62.6% |
| Intellipharmaceutics International Inc. | - USD | -Infinity% |
| Propanc Biopharma, Inc. | 58.64 Thousand USD | -13235.084% |
| Mesoblast Limited | 100.29 Million USD | 92.203% |
| Marizyme, Inc. | 667.12 Thousand USD | -1072.181% |
| Genus plc | 228.2 Million USD | 96.573% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 166.1 Million USD | 95.292% |
| Therapeutic Solutions International, Inc. | 5512.00 USD | -141771.553% |
| CNBX Pharmaceuticals Inc. | - USD | -Infinity% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| ContraFect Corporation | 2.21 Million USD | -253.844% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.4 Million USD | -457.4% |
| IMV Inc. | 27.39 Million USD | 71.459% |
| AXIM Biotechnologies, Inc. | 5.42 Million USD | -44.107% |
| MultiCell Technologies, Inc. | 36.43 USD | -21465615.07% |
| ONE Bio Corp. | 592.19 Thousand USD | -1220.498% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 55.61 Million USD | 85.938% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | - USD | -Infinity% |
| Q BioMed Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 2.22 Million USD | -251.301% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -536.617% |
| Biomind Labs Inc. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 554.59 Thousand USD | -1310.043% |
| Provectus Biopharmaceuticals, Inc. | 25.29 Thousand USD | -30810.155% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 1.89 Million USD | -311.909% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| GB Sciences, Inc. | 322 Thousand USD | -2328.559% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 11.23 Billion USD | 99.93% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | 150 Thousand USD | -5113.307% |
| Enzolytics Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 164.2 Thousand USD | -4662.315% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 15.35 Million USD | 49.069% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 4456.00 USD | -175392.819% |
| Genscript Biotech Corporation | 287.12 Million USD | 97.277% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 126.3 Thousand USD | -6091.478% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -3310.496% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| Kadimastem Ltd | 229.69 Thousand USD | -3304.557% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 8.26 Million USD | 5.373% |
| BioStem Technologies, Inc. | 265.63 Thousand USD | -2843.874% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 1064.00 USD | -734858.647% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -5126.757% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -5126.757% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | - USD | -Infinity% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | 141 Thousand USD | -5446.071% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| SYBLEU INC | 300 Thousand USD | -2506.653% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 369.04 Thousand USD | -2018.949% |
| International Stem Cell Corporation | 445 Thousand USD | -1657.294% |
| Bioxytran, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.15 Million USD | 4.05% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | 457 Thousand USD | -1611.151% |
| Neutra Corp. | - USD | -Infinity% |
| Windtree Therapeutics, Inc. | 1.16 Million USD | -573.554% |
| PureTech Health plc | 18.25 Million USD | 57.151% |
| Coeptis Therapeutics, Inc. | 150 Thousand USD | -5113.307% |
| IXICO plc | 275 Thousand USD | -2743.622% |
| IntelGenx Technologies Corp. | 11.83 Million USD | 33.947% |
| Gelesis Holdings, Inc. | 26.3 Million USD | 70.276% |
| CSL Limited | 11.23 Billion USD | 99.93% |
| Cellectis S.A. | 36.21 Million USD | 78.405% |